An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
|Articles|November 4, 2021
Daily OTC Pearl: Preparation H
Author(s)Saro Arakelians, PharmD
Preparation H works by temporarily narrowing the blood vessels in the area, which decreases swelling and discomfort caused by hemorrhoids.
Advertisement
OTC/Lifestyle Pearl of the Day: Preparation H
Indication: Preparation H is used to temporarily relieve swelling, burning, pain, and
Insight:
- Preparation H contains
phenylephrine , which belongs to a class of drugs known as sympathomimetic amines. - It works by temporarily narrowing the
blood vessels in the area, which decreases swelling and discomfort. - Directions: Use Preparation H up to 4 times daily, usually in the morning and
bedtime , after eachbowel movement , or as directed by a physician. - If symptoms do not improve within 7 days, if bleeding/worsening pain occurs, or if you think you may have a serious medical problem, consult a physician promptly.
- Active Ingredients: Mineral oil - 14.0 % (protectant), petrolatum - 74.9 % (protectant), phenylephrine HCL - 0.25 % (vasoconstrictor)
- Adverse events include fast/irregular heartbeat, pounding headache, nervousness, shakiness (tremor), and trouble sleeping.
Sources:
Advertisement
Related to this article
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5